Roth Capital Raises Price Target on Lannett (LCI) Following Acquisition of Kremers Urban Pharmaceuticals

After-Hours Stock Movers 09/02: (GERN) (LCI) (SEAC) Higher; (FIVE) (PLNT) (VRNT) Lower (more...)

Geron Corp (NASDAQ: GERN) 18.7% HIGHER; announced the publication of two papers in The New England Journal of Medicine (NEJM) in which the companys telomerase inhibitor, imetelstat, was shown to have disease-modifying activity thought to be associated with selective inhibition of the malignant progenitor cell clones responsible for the underlying disease in two hematologic myeloid... More

Market Wrap: Private Job Gains Lag in August; Valeant Makes New Acquisition; Baxalta Ends ARIAD Effort

Market wrap for September 2nd

End of the Day: S&P 500 up 35.0 to 1,948.86; Dow Jones up 293.0 to 16,351.38; Nasdaq up 113.9 to 4,749.98

Market Brief: Markets rebounded Wednesday following a selloff Tuesday over additional worries of a slowdown in China.

Private payroll additions rose less than expected last month, while nonfarm productivity outpaced in Q2.

Valeant moved to acquire Synergetics.

Republic Airways popped as teamsters said they were open to negotiations.

Tesla's Musk gave a Model 3 time frame update.

Crude prices rose 1.9 percent to... More

Lannett (LCI) to Acquire Kremers Urban Pharmaceuticals in $1.23B + Contingency Payments Deal

Lannett (NYSE: LCI) announced that it has signed a definitive agreement to purchase Kremers Urban Pharmaceuticals Inc. (KU), the U.S. specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB S.A., for $1.23 billion, plus potential contingency payments. Lannett believes the acquisition will be accretive to adjusted EPS in fiscal 2016 in the mid- to high-single digits and 20% to 25% in fiscal 2017. Lannett expects to receive a significant tax benefit as a result of 338(h)(10) election with a value in excess of $100 million. Lannett expects to fund the transaction with a combination of a... More